VRX.TO - Valeant Pharmaceuticals International, Inc.

Toronto - Toronto Delayed Price. Currency in CAD
30.80
-1.06 (-3.33%)
As of 4:00PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close31.86
Open31.96
Bid30.75 x 0
Ask30.89 x 0
Day's Range30.75 - 32.19
52 Week Range14.01 - 36.02
Volume1,232,408
Avg. Volume1,161,937
Market Cap10.585B
Beta-1.49
PE Ratio (TTM)N/A
EPS (TTM)-2.62
Earnings DateAug 7, 2018 - Aug 13, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend Date2010-11-10
1y Target Est21.20
  • Barrons.com2 hours ago

    Bausch Health Has New Name, Old Valeant Problems

    Valeant Pharmaceuticals International changed its name to Bausch Health (BHC), but Piper Jaffray's David Amsellem thinks the stock is a sell no matter what you call it. Amsellem reiterated an Underweight rating on Bausch on Monday, writing that the while the name change "refreshingly consigns the Valeant name to the dustbin of pharma history," and while that may help the company put some missteps behind it, he still has "myriad concerns regarding the commercial portfolio and pipeline." He writes that it's still too soon to say when and where Bausch's earnings before interest, taxes, depreciation and amortization will trough. The recent tentative approval of a generic form of  the non-steroid anti-inflammatory drug Apriso only serves to further highlight the company's "significant exposure to loss of exclusivities." Moreover, Amsellem writes that data points about new drug launches, specifically inflammatory treatment Siliq and eye drug Vyzulta "are suggestive of underwhelming traction." Given this, along with the company's exposure to mature assets with "questionable durability and leverage ratios that are still very much an eyesore" he thinks Bausch's valuation of 10 times enterprise value to Ebitda is still too high.

  • Why Bausch Health Companies Stock Has Gained Nearly 12% Halfway Through 2018
    Motley Fool4 days ago

    Why Bausch Health Companies Stock Has Gained Nearly 12% Halfway Through 2018

    A strong first-quarter sent the pharmaceutical company's shares northward, but this positive momentum is starting to fade after a key regulatory setback.

  • Valeant Pharmaceuticals before Its Q2 2018 Earnings
    Market Realist7 days ago

    Valeant Pharmaceuticals before Its Q2 2018 Earnings

    Valeant Pharmaceuticals (VRX), now known as Bausch Health Companies (BHC), generated revenues of $2 billion in the first quarter compared to $2.1 billion in the first quarter of 2017, reflecting a 5% YoY (year-over-year) decline.

  • Analyst Recommendations for Valeant Pharmaceuticals in July
    Market Realist7 days ago

    Analyst Recommendations for Valeant Pharmaceuticals in July

    In July, the FDA accepted Bausch + Lomb’s NDA (New Drug Application) for sub-micron loteprednol etabonate for the treatment of patients who have undergone ocular surgery and are showing symptoms of post-operative inflammation and pain.

  • Implied Volatility Surging for Valeant Pharmaceuticals (VRX) Stock Options
    Zacks7 days ago

    Implied Volatility Surging for Valeant Pharmaceuticals (VRX) Stock Options

    Investors in Valeant Pharmaceuticals (VRX) need to pay close attention to the stock based on moves in the options market lately.

  • Baystreet7 days ago

    Looking for Healthcare Exposure in Canada? Try This ETF

    Attempting to invest in the health-care sector in Canada is a difficult task, due primarily to the fact ...

  • ACCESSWIRE14 days ago

    Today's Research Reports on Acerus Pharmaceuticals, IMV, Valeant Pharmaceuticals and BELLUS Health

    NEW YORK, NY / ACCESSWIRE / July 9, 2018 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with ...

  • Despite FDA Rejection, Valeant (TSX:VRX) Stock Is Ready to Soar
    The Motley Fool17 days ago

    Despite FDA Rejection, Valeant (TSX:VRX) Stock Is Ready to Soar

    Why investors ought not to be dissuaded by an FDA rejection for a key Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) psoriasis cream.

  • Legal Marijuana Could Be a Solution to the Opioid Epidemic! 1 Pharma Company That May Wish to Get Into the Weed Space
    The Motley Fool20 days ago

    Legal Marijuana Could Be a Solution to the Opioid Epidemic! 1 Pharma Company That May Wish to Get Into the Weed Space

    Here's a company that may make a splash in the cannabis-based pharmaceuticals space, and it's not a producer like Canopy Growth Corp. (TSX:WEED)!

  • MarketWatch22 days ago

    Valeant is back on to its old drug-pricing ways

    A controversy over massive price increases, along with other scandals, wrecked Valeant Pharmaceutical International Inc.’s reputation as well as its stock price in recent years. Valeant (VRX) is using two techniques to raise prices on one of its best-selling drugs: it has increased the size of the package of its diarrhea medication, called Xifaxan, by 43%, from 42 pills to 60, and it is charging about 6% more per milligram, according to an analyst note by Mizuho’s Irina Koffler. The larger packaging has helped boost sales volumes, Koffler said.

  • Understanding How Your Psychological Makeup Can Affect Your Investment Decisions
    The Motley Fool23 days ago

    Understanding How Your Psychological Makeup Can Affect Your Investment Decisions

    Learn how your own psychological makeup can provide valuable insights as to whether a stock like Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) is the right fit for you.

  • Barrons.com24 days ago

    Valeant: It's More Than Just Dermatology

    Shares of Valeant Pharmaceuticals International (VRX) sold off earlier this month after the company received a Complete Response Letter from the Food and Drug Administration concerning its plaque psoriasis Duobrii.  However, Mizuho's Irina Koffler argues that the selloff is overdone, as she believes that Xifaxan, the traveler's diarrhea and irritable-bowel-syndrome treatment, is Valeant's key growth driver, rather than its dermatology portfolio.  She reiterated a Buy rating on Valeant Friday and raised her price target by $4 to $31. The SPDR S&P Pharmaceuticals ETF (XPH) is up 0.5% to $43.18 and the Health Care Select Sector SPDR ETF (XLV) is up 0.8% to $83.92.

  • Are You Keeping Tabs on What Management Is Doing With Your Money?
    The Motley Fool24 days ago

    Are You Keeping Tabs on What Management Is Doing With Your Money?

    Find out what you can do to keep yourself from staying up at night wondering about what companies like Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) are doing with your hard-earned money.

  • Understanding Leverage: The Gift and the Curse
    The Motley Fool25 days ago

    Understanding Leverage: The Gift and the Curse

    Leverage can be both a gift and a curse. Find out what makes the cases of Dollarama Inc. (TSX:DOL) and Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) so different.

  • Why Has Valeant Stock Fallen in June?
    Market Realist25 days ago

    Why Has Valeant Stock Fallen in June?

    Valeant Pharmaceuticals (VRX) stock has been falling in June. Valeant’s division Ortho Dermatologics received a CRL (complete response letter) from the FDA on June 18 for its new drug application for Duobril, which treats plaque psoriasis. Valeant’s Siliq, which treats moderate to severe psoriasis, received FDA approval earlier.

  • Barrons.com26 days ago

    A Win for Valeant: Treatment to Aid Opioid Addiction

    By now, we've all  heard of the horrors of the U.S. opioid crisis: Well over 100 people a day die by opioid overdose, and a quarter of all patients who are prescribed opioids for chronic pain–11.5 million people–end up misusing the medications. Valeant is off 0.5% to $23.19 this morning.

  • The Best Turnaround Stocks for the Second Half of 2018
    The Motley Fool26 days ago

    The Best Turnaround Stocks for the Second Half of 2018

    BlackBerry Ltd. (TSX:BB)(NYSE:BB) and Bombardier, Inc. (TSX:BBD.B) are two turnaround stocks that investors should consider as growth drivers for 2018 and beyond.

  • Why Aurora Cannabis Inc. (TSX:ACB) Could Skyrocket Like a Bat Out of Heck
    The Motley Fool28 days ago

    Why Aurora Cannabis Inc. (TSX:ACB) Could Skyrocket Like a Bat Out of Heck

    Aurora Cannabis Inc. (TSX:ACB) is a strong buy on the dip. Here's why the shareholder-dilutive acquisitions may not be as insidious as investors believe them to be.

  • CNBClast month

    Cramer's lightning round: I don't like Snap's ownership structure

    Jim Cramer shares his take on callers' favorite stocks at lightning speed, including a much debated social media play.

  • CNBClast month

    The woman behind 'female Viagra' sold her company for $1 billion — then got it back for free

    In 2015, Cindy Eckert (then Whitehead) made headlines after landing a billion-dollar deal for the company she co-founded, Sprout Pharmaceuticals, which developed female libido-boosting drug Addyi. Eckert co-founded Sprout Pharmaceuticals with her then-husband Robert Whitehead in 2011 to acquire a medication called flibanserin. With it, Sprout developed Addyi, dubbed "female Viagra," to treat hypoactive sexual desire disorder in premenopausal women ( 10 percent of all women suffer from HSDD).

  • Valeant Pharmaceuticals Intl Inc. (TSX:VRX) Recovery Hits a Roadblock
    The Motley Foollast month

    Valeant Pharmaceuticals Intl Inc. (TSX:VRX) Recovery Hits a Roadblock

    Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) may have hit a stumbling block with one of the Significant Seven, but long-term investors should stay the course.

  • Valeant Down as FDA Refuses to Approve Duobrii For Psoriasis
    Zackslast month

    Valeant Down as FDA Refuses to Approve Duobrii For Psoriasis

    Valeant (VRX) suffers a setback as the FDA issues a CRL for its plaque psoriasis lotion, Duobrii.

  • Barrons.comlast month

    Valeant's FDA Letter: Don't Write Off the Stock Yet

    Shares of Valeant Pharmaceuticals International (VRX) started the week off on a down note, on news that the company received a Complete Response Letter from the Food and Drug Administration concerning its plaque psoriasis treatment Monday, and the shares are falling again today. Cantor Fitzgerald argued that the letter wasn't anything for investors to worry about, and today H.C. Wainwright analyst Raghuram Selvaraju argues much the same thing, even if he has a Neutral rating on the stock. Selvaraju writes that although the psoriasis drug, Duobrii, was one of the "Significant Seven" products around which he saw the "new" Valeant would be built, he--much like Cantor--hasn't included sales from the treatment in his model for 2018.

  • Company News For Jun 19, 2018
    Zackslast month

    Company News For Jun 19, 2018

    Companies in the news are: JD,GOOGL,VRX,SLDB,TSLA

  • Why Valeant Pharmaceuticals' Stock Tumbled 12.3% Today
    Motley Foollast month

    Why Valeant Pharmaceuticals' Stock Tumbled 12.3% Today

    The FDA has dealt the company some disappointing news on one of its late-stage drugs.